RAD BIOMED ACCELERATOR ADDS PLEXICURE TO ITS PORTFOLIO
-- Plexicure is a joint venture between RAD BioMed, Israeli vernture capital Pontifax and Roche Pharmaceuticals --
Tel – Aviv, Israel, January 1st, 2011 – RAD BioMed, a leading success-accelerator for Israeli life science startups, today announced that it has added Plexicure, a new biopharma company that will be developed as a joint venture with Israeli venture capital firm Pontifax , in partnership with Roche AG (SWX: RO).
Plecxicure will be developing novel therapeutic antibodies with anti-angiogenic and anti-proliferative properties, based on technologies developed at the Rappaport Family Institute for Research in the Medical Sciences at the Technion Institute of Technology, Haifa.
Plexicure received approval for funding from the OCS Incubator program, and will start operations in March 2011
About RAD BioMed
RAD BioMed is a success-accelerator for Israeli life science startups. With state-of-the-art facilities, a team of entrepreneurial experts and broad contact networks, RAD BioMed incubates startups at various stages in the medical devices, biopharma and diagnostic sectors. The Tel-Aviv-based accelerator empowers innovation by ‘de-risking’ the start-up process and providing comprehensive support, including funding, mentoring and umbrella business development, marketing and administration services. RAD BioMed is the sole incubator in Israel to provide its portfolio companies with access to state-of-the-art biotechnology laboratories. RAD BioMed is owned by Yehuda Zisapel, President and Founder of the RAD Group, a world leader in voice and data communications technologies, and Professor Nava Zisapel, founder of Neurim Ltd., one of Israel’s leading BioPharma companies. RAD BioMed’s professional staff includes seasoned entrepreneurs and veteran professionals with broad experience in finance, medicine and biotechnology.